TY - JOUR
T1 - Cell surface markers for mesenchymal stem cells related to the skeletal system
T2 - A scoping review
AU - Fonseca, Luisa Nathalia
AU - Bolívar-Moná, Santiago
AU - Agudelo, Tatiana
AU - Beltrán, Liz Daniela
AU - Camargo, Daniel
AU - Correa, Nestor
AU - Del Castillo, María Alexandra
AU - Fernández de Castro, Sebastián
AU - Fula, Valeria
AU - García, Gabriela
AU - Guarnizo, Natalia
AU - Lugo, Valentina
AU - Martínez, Liz Mariana
AU - Melgar, Verónica
AU - Peña, María Clara
AU - Pérez, Wilfran Arbey
AU - Rodríguez, Nicolás
AU - Pinzón, Andrés
AU - Albarracín, Sonia Luz
AU - Olaya, Mercedes
AU - Gutiérrez-Gómez, María Lucía
N1 - Publisher Copyright:
© 2023 The Authors
PY - 2023/2
Y1 - 2023/2
N2 - Multipotent mesenchymal stromal cells (MSCs) have been described as bone marrow stromal cells, which can form cartilage, bone or hematopoietic supportive stroma. In 2006, the International Society for Cell Therapy (ISCT) established a set of minimal characteristics to define MSCs. According to their criteria, these cells must express CD73, CD90 and CD105 surface markers; however, it is now known they do not represent true stemness epitopes. The objective of the present work was to determine the surface markers for human MSCs associated with skeletal tissue reported in the literature (1994–2021). To this end, we performed a scoping review for hMSCs in axial and appendicular skeleton. Our findings determined the most widely used markers were CD105 (82.9%), CD90 (75.0%) and CD73 (52.0%) for studies performed in vitro as proposed by the ISCT, followed by CD44 (42.1%), CD166 (30.9%), CD29 (27.6%), STRO-1 (17.7%), CD146 (15.1%) and CD271 (7.9%) in bone marrow and cartilage. On the other hand, only 4% of the articles evaluated in situ cell surface markers. Even though most studies use the ISCT criteria, most publications in adult tissues don't evaluate the characteristics that establish a stem cell (self-renewal and differentiation), which will be necessary to distinguish between a stem cell and progenitor populations. Collectively, MSCs require further understanding of their characteristics if they are intended for clinical use.
AB - Multipotent mesenchymal stromal cells (MSCs) have been described as bone marrow stromal cells, which can form cartilage, bone or hematopoietic supportive stroma. In 2006, the International Society for Cell Therapy (ISCT) established a set of minimal characteristics to define MSCs. According to their criteria, these cells must express CD73, CD90 and CD105 surface markers; however, it is now known they do not represent true stemness epitopes. The objective of the present work was to determine the surface markers for human MSCs associated with skeletal tissue reported in the literature (1994–2021). To this end, we performed a scoping review for hMSCs in axial and appendicular skeleton. Our findings determined the most widely used markers were CD105 (82.9%), CD90 (75.0%) and CD73 (52.0%) for studies performed in vitro as proposed by the ISCT, followed by CD44 (42.1%), CD166 (30.9%), CD29 (27.6%), STRO-1 (17.7%), CD146 (15.1%) and CD271 (7.9%) in bone marrow and cartilage. On the other hand, only 4% of the articles evaluated in situ cell surface markers. Even though most studies use the ISCT criteria, most publications in adult tissues don't evaluate the characteristics that establish a stem cell (self-renewal and differentiation), which will be necessary to distinguish between a stem cell and progenitor populations. Collectively, MSCs require further understanding of their characteristics if they are intended for clinical use.
KW - Bone
KW - Bone marrow
KW - Cartilage
KW - Cell surface marker
KW - Mesenchymal stem cell (MSCs)
UR - http://www.scopus.com/inward/record.url?scp=85148749300&partnerID=8YFLogxK
U2 - 10.1016/j.heliyon.2023.e13464
DO - 10.1016/j.heliyon.2023.e13464
M3 - Article
AN - SCOPUS:85148749300
SN - 2405-8440
VL - 9
JO - Heliyon
JF - Heliyon
IS - 2
M1 - e13464
ER -